General information

Selection criteria

Cohorts

Expansion cohort: stage III

Collaboration

Publications

Available compounds per December 2023

Drug Target genes
Abemaciclib CCND1, CCND3, CDK4, CDK6, CCND2, CCND1 3’UTR
Alectinib ALK
Alpelisib PIK3CA, PIK3R1/2, PTEN
Atezolizumab + bevacizumab TMB-H ≥ 16 mut/Mb (all panels)
Axitinib KDR, FLT4
Crizotinib ALK, MET, MST1R, ROS1
Dabrafenib BRAF V600
Dabrafenib + trametinib BRAF
Dacomitinib EGFR, HER2, HER4
Durvalumab MSI
Erdafitinib FGFR1, FGFR2, FGFR3, FGFR4
Erlotinib EGFR, MAML2
Entrectinib ROS1
Lenvatinib FGFR1, FGFR2, FGFR3, FGFR4
Lorlatinib ALK, ROS1
Nilotinib KIT, ABL1, PDGFRa, PDGFRb
Niraparib BRCA1, BRCA2, RAD51C, RAD51D, PALB2, HRD-signature
Nivolumab + ipilimumab HML: >199 and < 1000, TMB-H:15–39 (TSO500) or 11–24 (Oncomine pane)
Olaparib ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD54L
Panitumumab RAF/RAS wildtype
Selpercatinib RET
Sunitinib CSF1R, FGFR1, FGFR2, FGFR3, FLT3, KDR, FLT4, KIT, PDGFRa, PDGFRb, RET
Talazoparib ATM, ATR, FANCA, FANCC, FANCD2, FANCF, FANCM, RAD51, RAD51B, RAD54L, NBN, MRE11, BARD1, BRIP1, CHEK1, CHEK2, PALB2, RABAC1 (PRA1), HRD signature
Trametinib MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K4, MAP3K1, NRAS, GNA11, GNAQ, GNAS, BRAF, NF1
Trastuzumab + pertuzumab HER2
Vemurafenib + cobimetinib BRAF
Vismodegib PTCH1

Onderstaand een overzicht van de geopende cohorten. Indien een geschikte patiënt zich voordoet die niet in een van deze cohorten past, kan er in overleg met het studieteam een nieuw cohort geopend worden.

Drug Tumor type Target Status
Abemaciclib Esophageal CCND3 amp Closed
Abemaciclib HNSCC CCND1 amp Closed
Abemaciclib Melanoma CCND1 amp Closed
Abemaciclib Ovarian CCND1 amp Closed
Abemaciclib Prostate CCND1 amp Closed
Abemaciclib Sarcoma CDK4 amp Closed
Abemaciclib SCC bladder CCND1 amp Closed
Abemaciclib Urachal cancer CCND1 amp Closed
Abemaciclib Carcinoma of the small intestine CCND3amp Closed
Abemaciclib Carcinoma of the small intestine CDK4 amp Closed
Abemaciclib Urinary tract CCND1 amp Closed
Abemaciclib Melanoma CDK4 amp Closed
Abemaciclib CRC CCND1 amp Closed
Abemaciclib Tumor agnostic cohort for CCND3ampl tumors (no NSCLC or CNS tumors) CCND3amp On hold
Abemaciclib Astrocytoma CCND1 amp Open
Abemaciclib Glioblastoma CDK4 amp Open
Abemaciclib NSCLC CCND1 amp On hold
Abemaciclib NSCLC CDK4ampl On hold
Abemaciclib Tumor agnostic cohort for patients with CCND1 amplification (no NSCLC or CNS tumors) CCND1amp On hold
Abemaciclib Tumor agnostic cohort for CDK4 ampl tumors (no NSCLC or CNS tumors) CDK4ampl On hold
Abemaciclib Tumor agnostic cohort for CCND2amp tumors (no NSCLC or CNS tumors) CCND2amp On hold
Afatinib NSCLC NRG1 fusion Closed
Alectinib Tumor-agnostic ALK fusion Open
Alectinib Tumor-agnostic ALK mut/amp Open
Alpelisib Gynaecological tumors AKT1 mut Closed
Alpelisib Tumor-agnostic Double hit Open
Alpelisib Anal cancer PIK3R2 mut Open
Alpelisib Gynaecological tumors PTEN loss Open
Alpelisib Gynaecological SCC PIK3CA mut Open
Alpelisib Gynaecological PCC PIK3CA mut Open
Alpelisib HNSCC PIK3Ca mut Open
Alpelisib Miscellaneous tumors PIK3CA mut Open
Alpelisib Prostate PIK3CA mut Open
Alpelisib Prostate PTEN loss Open
Alpelisib Renal cell PTEN loss Open
Alpelisib Salivary gland PTEN loss Open
Alpelisib Upper-GI PIK3CA mut Open
Alpelisib Radiation associated sarcoma/sarcomatoid carcinoom PTENloss Open
Alpelisib Cholangiocarcinoma PTENloss Open
Alpelisib Folliculair schildkliercarcinoom PTEN loss Open
Alpelisib Speekselkliercarcinoom PIK3R1 Open
Atezolizumab + bevacizumab Tumor-agnostic TMB ≥16 mut/Mb  Open
Axitinib CRC FLT1 amp Closed
Cabozantinib Esophageal MET mut Closed
Cabozantinib GIST NTRK2 mut Closed
Cabozantinib Melanoma MET amp Closed
Cabozantinib NSCLC Ret fusion Closed
Cabozantinib Esophageal RET mut Closed
Cabozantinib NSCLC MET mut Closed
Cabozantinib Teratoma MET amp Closed
Crizotinib NSCLC MET mut Closed
Crizotinib ACUP ALK fusion Open
Crizotinib Biliary tract ALK mut Open
Crizotinib Colorectal ALK mut Open
Crizotinib Colorectal MET amp Open
Crizotinib Esophageal MET amp Open
Crizotinib Gastric MET amp Open
Crizotinib Inflammatory myofibroblastic tumor ALK fusion Open
Crizotinib Hepatocellular MET amp Open
Crizotinib NSCLC MET amp Open
Crizotinib Thyroid ALK mut Open
Crizotinib Thyroid MET fusion Open
Crizotinib Gynaecological tumors MET amp Open
Crizotinib Sarcoma ALK Open
Crizotinib Renal cell MET mut Open
Dabrafenib Glioblastoma BRAF V600 mut Closed
Dabrafenib Urinary tract BRAF V600 mut Closed
Dabrafenib + trametinib NSCLC BRAF V600 mut Closed
Dabrafenib + trametinib Biliary tract BRAF V600 mut Closed
Dabrafenib + trametinib GIST BRAF V600 mut Closed
Dabrafenib + trametinib Glioblastoma BRAF V600 mut Open
Dabrafenib + trametinib Glioma (grade 3) BRAF V600 mut Open
Dabrafenib + trametinib Low grade glioma BRAF V600 mut Open
Dabrafenib + trametinib Mamma BRAF V600 mut Closed
Dabrafenib + trametinib Neuroendocrine carcinoma colon BRAF V600 mut Closed
Dabrafenib + trametinib Pancreas BRAF V600 mut Closed
Dacomitinib Breast HER2 mut Open
Dacomitinib Cervix HER2 mut Open
Dacomitinib Vagina HER2 mut Open
Dacomitinib Colorectal EGFR amp Open
Dacomitinib Colorectal HER2 amp Open
Dacomitinib Endometrial HER2 amp Open
Dacomitinib Endometrial HER2 mut Open
Dacomitinib Esophageal HER2 amp Open
Dacomitinib Gastric carcinoma HER2 amp Open
Dacomitinib Gastro-esophageal junction HER2 amp Open
Dacomitinib Penile HER2 fusion Open
Dacomitinib Penile EGFR amp Open
Dacomitinib Urinary tract EGFR amp Open
Dacomitinib Vulvar EGFR ampl Open
Dacomitinib Esophageal EGFR ampl Open
Dacomitinib Biliary tract EGFR ampl Open
Durvalumab Tumor-agnostic MSI Closed
Erdafitinib Plexus choroidea carcinoma FGFR2ampl Open
Erdafitinib CRC FGFR1ampl Open
Erdafitinib Breast FGFR1amp Open
Erdafitinib Pancreas FGFR3ampl Open
Erdafitinib Prostate FGFR3ampl Open
Erdafitinib NSCLC FGFR1ampl Open
Erdafitinib Ovarian FGFR1ampl Open
Erdafitinib CUP FGFR1ampl Open
Erdafitinib Endometrial FGFR1 ampl Open
Erlotinib CRC EGFR mut Open
Erlotinib Glioblastoma EGFR fusion Open
Erlotinib Glioblastoma EGFR mut Open
Erlotinib Anaplastic astrocytoma EGFR mut Open
Lenvatinib Adenoid cystic carcinoma FGFR2 mut Open
Lenvatinib ACUP FGFR2 fusion Open
Lenvatinib Anal cancer FGFR3 mut Open
Lenvatinib Anaplastic thyroid FGFR3 mut Open
Lenvatinib Ameloblastoma FGFR2 mut Open
Lenvatinib Biliary tract FGFR2 fusion Open
Lenvatinib Biliary tract FGFR3 fusion Open
Lenvatinib Biliary tract FGFR2 mut Open
Lenvatinib Biliary tract FGFR3 mut Open
Lenvatinib Cervix FGFR3 mut Open
Lenvatinib Colorectal FGFR1 amp Open
Lenvatinib Colorectal FGFR2 amp Open
Lenvatinib Endometrial FGFR2 mut Open
Lenvatinib Endometrial FGFR3 amp Open
Lenvatinib Esophageal FGFR2 amp Open
Lenvatinib Glioblastoma FGFR3 fusion Open
Lenvatinib Glioneural tumor FGFR1 mut Open
Lenvatinib Glioma FGFR1 mut Open
Lenvatinib HNSCC FGFR3 mut Open
Lenvatinib Breast FGFR1 amp Open
Lenvatinib Breast FGFR2 amp/mut Open
Lenvatinib Neuroendocrine nasal cavity FGFR3 amp Open
Lenvatinib NSCLC FGFR1 amp Open
Lenvatinib NSCLC FGFR2 amp Open
Lenvatinib Osteosarcoma FGFR1 amp Open
Lenvatinib Pancreas FGFR1 amp Open
Lenvatinib Pancreas FGFR2 fusion Open
Lenvatinib Papillary  cancer FGFR2 mut Open
Lenvatinib Salivary gland FGFR3 amp Open
Lenvatinib Salivary duct FGFR2 mut Open
Lenvatinib Urachal cancer FGFR2 amp Open
Lenvatinib Urinary  tract FGFR3 mut Open
Lenvatinib Vagina FGFR3 mut Open
Lenvatinib Glioblastoma FGFR3 mut Open
Lenvatinib Sarcoma FGFR3 fusion Open
Lenvatinib NSCLC FGFR3 mut Open
Lorlatinib NSCLC ROS1 fusion Open
Lorlatinib Inflammatory myofibrolastic tumor ALK fusion Open
Lorlatinib Cutaneous adnexal carcinoma ROS-1 amp Open
Nilotinib GIST KIT mut Open
Nilotinib Colorectal PDGFRB amp Closed
Nilotinib Germ cell KIT mut Closed
Nilotinib GIST PDGFRA mut Closed
Nilotinib Melanoma KIT mut Closed
Nilotinib Mesothelioma PDGFRA mut Closed
Niraparib Tumor-agnostic HRD Open
Niraparib Primairy brain tumors HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) Open
Niraparib Lung cancer HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) Open
Niraparib MPM HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) Open
Niraparib All other tumor types HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) Open
Nivolumab Tumor-agnostic MSI (2nd stage) Closed
Nivolumab Tumor-agnostic MSI (3rd stage) Closed
Nivolumab Tumor-agnostic HML >450 Closed
Nivolumab + ipilimumab Tumor-agnostic HML 200-1000 Closed
Olaparib Tumor-agnostic BRCA mut/loss Closed
Olaparib Tumor-agnostic ATM mut/loss Closed
Olaparib Tumor-agnostic Other HRR alterations (breast, ovarian, prostate, pancreas, SCLC or stomach carcinoma) Closed
Olaparib Tumor-agnostic Other HRR alterations (all other tumor types) Open
Palbociclib Astrocytoma CDK4 amp Closed
Palbociclib Biliary tract CDKN2A loss/mut Closed
Palbociclib Colorectal CCND2 amp Closed
Palbociclib Colorectal CDKN2A loss/mut Closed
Palbociclib Colorectal SMARCA4 mut Closed
Palbociclib Duodenal CDKN2A loss/mut Closed
Palbociclib Endometrial carcinoma CDKN2A loss/mut Closed
Palbociclib Esophageal CDK4 amp Closed
Palbociclib Esophageal CDKN2A loss/mut Closed
Palbociclib Glioblastoma CDKN2A loss/mut Closed
Palbociclib HNSCC CDKN2A loss/mut Closed
Palbociclib Melanoma CCND1 amp Closed
Palbociclib Melanoma CDKN2A loss/mut Closed
Palbociclib Neuroendocrine tumor CDKN2A loss/mut Closed
Palbociclib Neuroendocrine tumor CCND1 amp Closed
Palbociclib NSCLC CCND1 amp Closed
Palbociclib NSCLC CDKN2A loss/mut Closed
Palbociclib (uvual) melanoma CDKN2A loss/mut Closed
Palbociclib Ovarian CDKN2A loss/mut Closed
Palbociclib Ovarian SMARCA4 mut Closed
Palbociclib Pancreas CDKN2A loss/mut Closed
Palbociclib PECoom CDK4 amp Closed
Palbociclib Primitive Neuro-ectodermal tumor CDKN2A loss/mut Closed
Palbociclib Prostate CDK4 amp Closed
Palbociclib Prostate CDK6 amp Closed
Palbociclib Renal cell CDKN2A loss/mut Closed
Palbociclib Sarcoma CDK4 amp Closed
Palbociclib Vulva carcinoma CDKN2A loss/mut Closed
Palbociclib Vulva carcinoma CCND1 amp Closed
Panitumumab Glioblastoma BRAF-KRAS-NRAS wildtype Closed
Panitumumab ACUP BRAF-KRAS-NRAS wildtype Open
Panitumumab Anal cancer BRAF-KRAS-NRAS wildtype Open
Panitumumab Cervix BRAF-KRAS-NRAS wildtype Open
Panitumumab Endometrial BRAF-KRAS-NRAS wildtype Open
Panitumumab Gynaecological SCC BRAF-KRAS-NRAS wildtype Open
Panitumumab HNSCC BRAF-KRAS-NRAS wildtype Open
Panitumumab Meningioma BRAF-KRAS-NRAS wildtype Open
Panitumumab (uvual) melanoma BRAF-KRAS-NRAS wildtype Open
Panitumumab NSCLC BRAF-KRAS-NRAS wildtype + EGFR mut/amp Open
Panitumumab Salivary duct BRAF-KRAS-NRAS wildtype Open
Panitumumab Sarcoma BRAF-KRAS-NRAS wildtype Open
Panitumumab Thyroid BRAF-KRAS-NRAS wildtype Open
Pembrolizumab Colorectal HML 140-290 Closed
Pembrolizumab HNSCC HML 140-290 Closed
Pembrolizumab Breast HML 140-290 Closed
Pembrolizumab Miscellaneous tumors HML 140-290 Closed
Pembrolizumab Prostate HML 140-290 Closed
Pembrolizumab Upper-GI HML 140-290 Closed
Pembrolizumab Tumor-agnostic HML > 290 Closed
Regorafenib Adenoid cystic carcinoma BRAF mut Closed
Regorafenib Duodenal FLT1 amp Closed
Regorafenib Melanoma KIT mut Closed
Regorafenib Esthesioneuroblastoma RET Closed
Regorafenib NSCLC RAF1 mut Closed
Regorafenib NSCLC RET Closed
Regorafenib Thymus KIT mut Closed
Ribociclib Anaplastic meningeoma CDKN2A loss/mut Closed
Ribociclib ACUP CDKN2A loss/mut Closed
Ribociclib Ceruminous adenocarcinoma CDKN2A loss/mut Closed
Ribociclib Ependymoma CDKN2A loss/mut Closed
Ribociclib Gastric cancer CDKN2A loss/mut Closed
Ribociclib Melanoma CDK4 amp Closed
Ribociclib Mesothelioma CDKN2A loss/mut Closed
Ribociclib Mucoepidermoid CDK6 amp Closed
Ribociclib Prostate CDKN2A loss/mut Closed
Ribociclib Salivary gland CDKN2A loss/mut Closed
Ribociclib Sarcoma CDKN2A loss/mut Closed
Ribociclib Thymus CDKN2A loss/mut Closed
Ribociclib Urinary tract CDKN2A loss/mut Closed
Rucaparib Breast HRR alterations Closed
Rucaparib Miscellaneous tumors HRR alterations Closed
Rucaparib Ovarian HRR alterations Closed
Rucaparib Pancreas HRR alterations Closed
Rucaparib Prostate HRR alterations Closed
Sunitinib Adenoid cystic carcinoma PDGFRA amp Open
Sunitinib Colorectal CSF1R mut Open
Sunitinib Colorectal FLT3 amp Open
Sunitinib Breast PDGFRB amp Open
Sunitinib Tumor-agnostic Multi-hit Open
Sunitinib NSCLC KIT amp Open
Sunitinib Osteosarcoma PDFGRB mut Open
Sunitinib Ovarian FGFR1 amp Open
Sunitinib Ovarian FGFR2 amp Open
Sunitinib Pancreas RET fusion Open
Sunitinib Pseudomyxoma peritonei FLT3 mut Open
Sunitinib Prostate PDFGRA mut Open
Sunitinib Thymus KIT mut Open
Sunitinib Thyroid cancer PDGFRB mut Open
Sunitinib Thyroid cancer PDGFRA mut Open
Sunitinib Urinary tract FGFR1 amp Open
Talazoparib Tumor-agnostic ATM/ATR alteraties Open
Talazoparib Tumor-agnostic HRD signature Open
Talazoparib Tumor-agnostic FANCA/FANCC/FANCD2/FANCF/FANC mut Open
Talazoparib Tumor-agnostic other mutations in HRR genes (BARD1/BRIP1/CHECK1/2/PALB2/RABAC1(PRA1)) Open
Trametinib ACUP MAP3K1mut Closed
Trametinib Cervix MAP3K1mut Closed
Trametinib Cholangiocarcinoma MAP2K4 mut Closed
Trametinib Colorectal MAP2K4 mut Closed
Trametinib Breast MAP3K1 mut Closed
Trametinib Breast MAP2K4 mut Closed
Trametinib Neuroendocrine carcinoma MAP3K1 mut Closed
Trametinib Ovarian MAP2K4 mut Closed
Trametinib Pancreas MAP2K4 mut Closed
Trametinib Prostate MAP3K1 mut Closed
Trametinib Colorectal MAP2K1 mut Closed
Trametinib Glioneural tumor BRAF fusion Closed
Trametinib Histiocytair sarcoma MAP2K1mut Closed
Trametinib Melanocytic tumor GNA11 mut Closed
Trametinib Neuroendocrine carcinoma NRAS mut Open
Trametinib NSCLC BRAF mut Closed
Trametinib NSCLC BRAF fusion Closed
Trametinib NSCLC MAP2K1 mut Closed
Trametinib NSCLC NRAS mut Open
Trametinib Ovarian NRAS mut Open
Trametinib Ovarian BRAF fusion Closed
Trametinib Pancreas BRAF fusie Closed
Trametinib (Pilocytic) astrocytoma BRAF fusion Closed
Trametinib Pleimorph tumor NRAS mut Open
Trametinib Prostate NRAS mut Open
Trametinib Salivary duct BRAF fusion Closed
Trametinib Salivary duct NRAS mut Open
Trametinib Thyroid NRAS mut Open
Trametinib Tumor-agnostic GNAS mut Closed
Trametinib Tumor-agnostic NF1 mut Closed
Trametinib Tumor-agnostic MAP2K1 mut Closed
Trametinib Urinary tract BRAF fusion Closed
Trametinib Yolk sac tumor NRAS mut Open
Trametinib Urethral carcinoma NRAS mut Open
Trametinib Cholangiocarcinoma NRASmut Open
Trastuzumab + pertuzumab Colorectal HER2 amp Closed
Trastuzumab + pertuzumab NSCLC HER2 mut Closed
Trastuzumab + pertuzumab Adenoid cystic carcinoma HER2 mut Open
Trastuzumab + pertuzumab Biliary tract HER2 amp Open
Trastuzumab + pertuzumab Cervix HER2 amp Open
Trastuzumab + pertuzumab Cervix HER2 mut Open
Trastuzumab + pertuzumab Colorectal HER2 mut Open
Trastuzumab + pertuzumab Duodenal HER2 amp Open
Trastuzumab + pertuzumab Hidradenocarcinoma HER2 amp Open
Trastuzumab + pertuzumab Melanoma HER2 amp Open
Trastuzumab + pertuzumab Neuroendocrine carcinoma HER2 amp Open
Trastuzumab + pertuzumab NSCLC HER2 amp Open
Trastuzumab + pertuzumab Ovarian HER2 amp Open
Trastuzumab + pertuzumab Ovarian HER2 mut Open
Trastuzumab + pertuzumab Salivary duct HER2 amp Open
Trastuzumab + pertuzumab Urinary tract HER2 amp Open
Trastuzumab + pertuzumab Urinary tract HER2 mut Open
Trastuzumab + pertuzumab Vulva HER2 amp Open
Trastuzumab + pertuzumab Goblet Cell Carcinoma HER2 mut Open
Vemurafenib + cobimetinib ACUP BRAF V600 mut Open
Vemurafenib + cobimetinib Biliary tract BRAF V600 mut Open
Vemurafenib + cobimetinib Erdheim Chester Disease BRAF V600 mut Open
Vemurafenib + cobimetinib NSCLC BRAF  non-V600 mut Open
Vemurafenib + cobimetinib Papillair craniopharyngeoma BRAF V600 mut Open
Vemurafenib + cobimetinib Prostate BRAF non-V600 mut Open
Vemurafenib + cobimetinib Thyroid BRAF V600 mut Open
Vemurafenib + cobimetinib Ovarian BRAF V600 mut Open
Vemurafenib + cobimetinib Salivary duct BRAF V600 mut Open
Vemurafenib + cobimetinib Sarcoma BRAF V600 mut Open
Vismodegib Sarcoma PTCH1 mut Open
Vismodegib CNS tumors PTCH1 mut Open
Entrectinib Tumor-agnostic ROS1 fusion Open
Dacomitinib Stomach cancer HER2 amp Open
Dabrafenib + trametinib Hairy Cell Leukemia BRAF mut Closed